Capricor Therapeutics (CAPR) Tops Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
November 7, 2019 4:00 PM ESTProvides Update on End of Phase Type-B Meeting with FDA
Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society
To Host Conference Call and Webcast Today at 4:30 p.m. ET
LOS ANGELES, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on... More
